Menarini licenses new gout treatment from Ipsen
This article was originally published in Scrip
Executive Summary
Menarini is to bring to market in Europe the first new treatment for chronic hyperuricaemia in gout in 40 years under a licensing agreement with Ipsen. The Italian firm plans to launch Adenuric (febuxostat) in the first markets early next year.